Drug intelligence / Profile preview

BAY98751

Development stage: Phase 1
Lead developer: Bayer
Modality: Small Molecules
Administration: Ophthalmic, Topical

Overview

BAY98751 is a compound developed by Bayer as a sunscreen agent. It has been evaluated in clinical trials for topical application to the eye, suggesting its use in ocular protection against ultraviolet (UV) radiation. The drug is not known to have systemic pharmacological activity beyond its function as a UV filter or sunscreen agent. There is no evidence it acts via receptor-mediated mechanisms or targets typical of pharmaceutical drugs; rather, it functions by physically or chemically blocking UV light from reaching tissues.

Other names: BAY-98751BAY98751BAY 98751Y65-110Y-65-110Y 65-110

Beyond the preview

Go deeper on BAY98751.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAY98751.

Explore the full profile